Haisco Pharmaceutical Group Co. Ltd. has synthesized DNA polymerase θ (POLθ) inhibitors reported to be useful for the treatment of cancer.

Bisichem Co. Ltd. has disclosed receptor-interacting serine/threonine-protein kinase 1 (RIPK1; RIP-1) inhibitors reported to be useful for the treatment of cancer, rheumatoid arthritis, asthma, stroke, amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer’s disease and Parkinson’s disease, among others.

Shenzhen Sungening Biotechnology Co. Ltd. has described kinesin-like protein KIF18A inhibitors reported to be useful for the treatment of cancer.

Ribopeutic Inc. has divulged nucleic acid splicing modulators (particularly, Huntingtin [HTT; HD] [mutant] and/or transcriptional activator Myb [c-Myb]) reported to be useful for the treatment of cancer and Huntington’s disease.

Henan Medinno Pharmaceutical Technology Co. Ltd. has identified deuterated non-receptor tyrosine-protein kinase TYK2 and tyrosine-protein kinase JAK1, JAK2 and JAK3 inhibitors reported to be useful for the treatment of allergy, asthma, cancer, dermatological disorders, diabetes, eye disorders, neurodegeneration and transplant rejection, among others.

Pharmaengine Inc. has synthesized protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of cancer.

Cancer Targeted Technology LLC has disclosed conjugates comprising a glutamate carboxypeptidase 2 (FOLH1; NAALAD1; PSMA) targeting ligand covalently linked to a therapeutic or diagnostic agent through a linker reported to be useful for the treatment of prostate cancer.

Accent Therapeutics Inc. has described ATP-dependent RNA helicase A (DHX9) inhibitors reported to be useful for the treatment of cancer.

Transthera Biosciences Co. Ltd. has divulged NLRP3 inflammasome inhibitors reported to be useful for the treatment of autoimmune diseases and inflammatory disorders.

Abbisko Therapeutics Co. Ltd. has identified EGFR mutant inhibitors reported to be useful for the treatment of cancer.